Brief: Akari Therapeutics Secures Australian Patent Approval
27/04/2026 13:58
April 27 (Reuters) - Akari Therapeutics PLC AKTX.O: AKARI THERAPEUTICS SECURES AUSTRALIAN PATENT APPROVAL, FURTHER EXPANDING GLOBAL PROTECTION OF ITS PROPRIETARY PH1 RNA SPLICING MODULATOR ADC PAYLOAD AKARI THERAPEUTICS PLC - AKTX-101 IN IND-ENABLING STUDIES WITH PHASE 1 TRIAL EXPECTED LATE 2026/EARLY 2027 Source text: ID:nGNX7dgdTZ Further company coverage: AKTX.O ((Reuters.Briefs@thomsonreuters.com;))